A Randomized, Double-Blind, Two Treatment, Two Period, Chronic Dosing (2 Weeks), Cross-Over, Single-Center Study to A Study to Assess the Effects of PT003 and Placebo MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPD
Latest Information Update: 17 Feb 2017
At a glance
- Drugs Formoterol/glycopyrrolate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 13 Feb 2017 Status changed from active, no longer recruiting to completed.
- 20 Jan 2017 New trial record